Supply of NIV Drugs to Directorate of Procurement (Navy), Islamabad

The Directorate of Procurement (Navy), Islamabad, invites sealed bids from original manufacturers, authorized distributors, and suppliers registered with income tax and sales tax departments for the supply of NIV Drugs as per the detailed schedule in DP-2 form. This procurement covers 29 specific drug items including Ondansetron 8 mg, Etoposide 100 mg, Capecitabine 500 mg, Bevacizumab (120 ml and 400 mg), Trastuzumab 600 mg, Rituximab (100 ml and 500 mg), Zoledronic Acid 4 mg, Thalidomide 100 mg, Entacavir 0.5 mg, Nebivolol 5 mg, Aspirin + Clopidogrel 75/75 mg, various combinations of Valsartan and Amlodipine, Rosuvastatin 10 and 20 mg, Vildagliptin, Sitagliptin, Duloxetine, Levetiracetam, and Moxifloxacin 400 mg. Items being procured: - Ondansetron 8 mg (50,000 units) - Etoposide 100 mg (300 units) - Capecitabine 500 mg (6,000 units) - Bevacizumab 120 ml (100 units) - Bevacizumab 400 mg (100 units) - Trastuzumab 600 mg (100 units) - Rituximab 100 ml (60 units) - Rituximab 500 mg (50 units) - Zoledronic Acid 4 mg (300 units) - Thalidomide 100 mg (1,500 units) - Entacavir 0.5 mg (12,000 units) - Nebivolol 5 mg (150,000 units) - Aspirin + Clopidogrel 75/75 mg (500,000 units) - Valsartan + Amlodipine 5/80 mg (800,000 units) - Valsartan + Amlodipine 5/160 mg (400,000 units) - Valsartan + Amlodipine 10/160 mg (300,000 units) - Valsartan + Hydrochlorothiazide 160/12.5 mg (50,000 units) - Amlodipine + Valsartan + Hydrochlorothiazide 5/80/12.5 mg (50,000 units) - Hydrochlorothiazide 12.5/50 mg + Losartan (K) (450,000 units) - Rosuvastatin 20 mg (300,000 units) - Rosuvastatin 10 mg (500,000 units) - Vildagliptin 50 mg (75,000 units) - Sitagliptin 50 mg (400,000 units) - Vildagliptin + Metformin 50/500 mg (100,000 units) - Vildagliptin + Metformin 50/1000 mg (150,000 units) - Duloxetine 30 mg (50,000 units) - Duloxetine 60 mg (25,000 units) - Levetiracetam 500 mg (250,000 units) - Moxifloxacin 400 mg (50,000 units) The technical scope requires compliance with detailed specifications, shelf life requirements, packaging standards, and delivery schedules for the fiscal year 2027-28. Delivery will be quarterly or as required, with a minimum 75% quantity acceptance by the consignee. Inspection will be conducted by Pakistan Navy Medical Stores Depot at Karachi and Islamabad. Firms must be registered or willing to register with DGDP and comply with PPRA Rules 2004 and DPP&I-35 (Revised 2024). Earnest money must be submitted as per category with a Call Deposit Receipt in favor of CMA (DP), Rawalpindi. The tender follows a Single Stage - Two Envelope bidding procedure with technical offers evaluated first. The tender closing date is **05 November 2026 at 1030 hours** with bid opening at 1100 hours the same day. Bids must be submitted in sealed envelopes at the Directorate of Procurement (Navy), Bahria Gate, Near SNID Centre, Naval Residential Complex, Sector E-8, Islamabad. Interested bidders should ensure all required documents including technical offers, commercial offers, earnest money, and registration certificates are complete and properly sealed. One practical tip for bidders is to carefully follow the prescribed format for technical and commercial offers, ensuring no overwriting or conditional offers, as non-compliance will lead to rejection. Also, ensure timely submission to avoid disqualification due to late receipt. This procurement offers a significant opportunity for pharmaceutical suppliers to engage with the Pakistan Navy for a comprehensive supply contract of essential medicines in Islamabad.